Funding Opportunities

Neuroendocrine cancer research grant types

NETRF offers three different neuroendocrine cancer research grants (Investigator, Pilot, and Mentored Awards) with cancer research grants ranging from $90,000 to $270,000. 

Seeking transformational ideas

We invite innovative and transformative research proposals in NETs to help bring the field closer to more effective therapies. We are equally interested in basic, translational and clinical research applications, and encourage collaborations between investigators with expertise in different fields. Prior research in NETs is not a prerequisite, and we encourage scientists to enter the NET research field.

Encouraging team science

We are very interested in grant proposals from multidisciplinary groups comprised of basic scientists, clinicians, and experts across relevant cutting-edge disciplines. Proposals that cover promising and potentially transferable strategies and/or technologies, which have been applied successfully to other areas of cancer research, are highly encouraged and will be evaluated based on their level of applicability to NETs.

Areas of Interest

Areas not exclusive or in order of preference:

  • Uncovering the molecular and genetic basics of NETs
  • New/optimized experimental models
  • Application of existing or new technologies to target NETs
  • Cancer metabolism
  • Cell invasion and metastasis
  • Tumor microenvironment
  • Immunotherapy
  • Diagnostics/Biomarkers
  • Big data
  • Clinical research
  • Nuclear medicine, theranostics, imaging

Organs of interest

While we recognize that neuroendocrine cancers can develop in many different organs, our focus includes:


Gastroenteropancreatic NETs, including sites of metastasis. 

Adrenal-Associated NETs 

Pheochromocytoma and paraganglioma. 

Neuroendocrine Carcinomas (NECs)

Extrapulmonary, high-grade neuroendocrine carcinomas.

Lung Carcinoids

Well-differentiated, low-grade typical carcinoids (TCs), well-differentiated, intermediate-grade atypical carcinoids (ACs), or diffuse idiopathic neuroendocrine cell hyperplasia (DIPNECH).

Currently, NETRF does not fund research in SCLC, LCLC, non-SCLC, squamous cell carcinomas, adenocarcinomas, mesotheliomas, poorly differentiated non–small cell lung carcinomas, or neuroendocrine prostate cancer.

See our FAQ for more information. Send an email to to join our researcher database.